Pharma Equity Group A/S (CPH:PEG)
Denmark · Delayed Price · Currency is DKK 0.1200
+0.0015 (1.27%)
Jul 25, 2025, 4:59 PM CET
Pharma Equity Group Company Description
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement.
Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma.
The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.
Pharma Equity Group A/S
| Country | Denmark |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Christian Tange |
Contact Details
Address: Slotsmarken 18 2. th. Horsholm, 2970 Denmark | |
| Phone | 45 41 92 25 25 |
| Website | pharmaequitygroup.com |
Stock Details
| Ticker Symbol | PEG |
| Exchange | Copenhagen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061155009 |
| SIC Code | 6799 |
Key Executives
| Name | Position |
|---|---|
| Sebastian Bo Jakobsen | Chief Executive Officer of Reponex Pharmaceuticals |
| Christian Henrik Tange | Chief Executive Officer |
| Peter Ekman | Financial Manager |
| Dr. Lars Otto Uttenthal | Chief Medical Officer |